The University of Chicago Header Logo

Connection

Sandeep Gurbuxani to Leukemia, Myeloid, Acute

Back to Details
This is a "connection" page, showing publications Sandeep Gurbuxani has written about Leukemia, Myeloid, Acute.
Sandeep Gurbuxani
Connection Strength
2.131
Leukemia, Myeloid, Acute
  1. The Times, They Are A-Changing: The Impact of Next-Generation Sequencing on Diagnosis, Classification, and Prognostication of Myeloid Malignancies With Focus on Myelodysplastic Syndrome, AML, and Germline Predisposition. Am Soc Clin Oncol Educ Book. 2023 Jun; 43:e390026.
    View in: PubMed
    Score: 0.559
  2. PHF6 suppresses self-renewal of leukemic stem cells in AML. Leukemia. 2024 Sep; 38(9):1938-1948.
    View in: PubMed
    Score: 0.151
  3. Durable responses in acute lymphoblastic leukaemia with the use of FLT3 and IDH inhibitors. Br J Haematol. 2024 Apr; 204(4):1238-1242.
    View in: PubMed
    Score: 0.145
  4. Clinical and molecular response of acute myeloid leukemia harboring non-canonical FLT3 N676K driver mutations to contemporary FLT3 inhibitors. Haematologica. 2023 08 01; 108(8):2234-2239.
    View in: PubMed
    Score: 0.141
  5. Oncogenic RAS promotes leukemic transformation of CUX1-deficient cells. Oncogene. 2023 03; 42(12):881-893.
    View in: PubMed
    Score: 0.136
  6. Therapy-related myeloid neoplasms with normal karyotype show distinct genomic and clinical characteristics compared to their counterparts with abnormal karyotype. Br J Haematol. 2022 06; 197(6):736-744.
    View in: PubMed
    Score: 0.128
  7. LKB1/STK11 Is a Tumor Suppressor in the Progression of Myeloproliferative Neoplasms. Cancer Discov. 2021 06; 11(6):1398-1410.
    View in: PubMed
    Score: 0.119
  8. FTO Plays an Oncogenic Role in Acute Myeloid Leukemia as a N6-Methyladenosine RNA Demethylase. Cancer Cell. 2017 01 09; 31(1):127-141.
    View in: PubMed
    Score: 0.089
  9. Eradication of Acute Myeloid Leukemia with FLT3 Ligand-Targeted miR-150 Nanoparticles. Cancer Res. 2016 08 01; 76(15):4470-80.
    View in: PubMed
    Score: 0.086
  10. Identification of MLL-fusion/MYC?miR-26?TET1 signaling circuit in MLL-rearranged leukemia. Cancer Lett. 2016 Mar 28; 372(2):157-65.
    View in: PubMed
    Score: 0.084
  11. PBX3 and MEIS1 Cooperate in Hematopoietic Cells to Drive Acute Myeloid Leukemias Characterized by a Core Transcriptome of the MLL-Rearranged Disease. Cancer Res. 2016 Feb 01; 76(3):619-29.
    View in: PubMed
    Score: 0.084
  12. Overexpression and knockout of miR-126 both promote leukemogenesis. Blood. 2015 Oct 22; 126(17):2005-15.
    View in: PubMed
    Score: 0.082
  13. TET1 plays an essential oncogenic role in MLL-rearranged leukemia. Proc Natl Acad Sci U S A. 2013 Jul 16; 110(29):11994-9.
    View in: PubMed
    Score: 0.070
  14. miR-9 is an essential oncogenic microRNA specifically overexpressed in mixed lineage leukemia-rearranged leukemia. Proc Natl Acad Sci U S A. 2013 Jul 09; 110(28):11511-6.
    View in: PubMed
    Score: 0.070
  15. MiR-495 is a tumor-suppressor microRNA down-regulated in MLL-rearranged leukemia. Proc Natl Acad Sci U S A. 2012 Nov 20; 109(47):19397-402.
    View in: PubMed
    Score: 0.067
  16. An integrated genomic approach to the assessment and treatment of acute myeloid leukemia. Semin Oncol. 2011 Apr; 38(2):215-24.
    View in: PubMed
    Score: 0.060
  17. Malignant progression of preleukemic disorders. Blood. 2024 05 30; 143(22):2245-2255.
    View in: PubMed
    Score: 0.037
  18. Loss of Mll3 Catalytic Function Promotes Aberrant Myelopoiesis. PLoS One. 2016; 11(9):e0162515.
    View in: PubMed
    Score: 0.022
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.